Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Adaptimmune Ther Ads (ADAP)

$1.73 0.02 (1.14%)

12:31 EDT ADAP Stock Quote Delayed 15 Minutes

Volume:

Previous Close $1.75

Market Cap 162.87M

PE Ratio -2.40

EPS -0.72

Volume (Avg. Vol.) 31,557

Day's Range 1.70 - 1.78

52-Week Range 1.37 - 14.54

Dividend & Yield N/A (N/A)

ADAP Stock Predictions, Articles, and Adaptimmune Ther Ads News

From the Web

71 Biggest Movers From Yesterday

From Benzinga Sep 12, 2019

Gainers T2 Biosystems, Inc. (NASDAQ: TTOO) shares jumped 82.5% to close at $2.61 on Wednesday after the company announced that it has been awarded a breakthrough technology...

25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

From Benzinga Sep 11, 2019

Gainers T2 Biosystems, Inc. (NASDAQ: TTOO) stock surged 30.1% to $1.86 during Wednesday's pre-market session. The market value of their outstanding shares is at $209.3...

26 Stocks Moving in Wednesday's Pre-Market Session

From Benzinga Sep 11, 2019

Gainers Yuma Energy, Inc. (NYSE: YUMA) rose 87.4% to $3.41 in pre-market trading after the company announced a third-party has purchased all of the company's outstanding...

MMSI, OLED, STOK and WEN among midday movers

From Seeking Alpha Sep 10, 2019

Gainers: Francesca's Holdings (NASDAQ:FRAN) +92%. Mallinckrodt plc (NYSE:MNK) +64%. Pier 1 Imports (NYSE:PIR) +41%. YRC Worldwide (NASDAQ:YRCW) +32%. Endo International (NASDAQ:ENDP) +29%. Dean Foods

Mallinckrodt leads healthcare gainers; Cesca Therapeutics among losers

From Seeking Alpha Sep 10, 2019

Gainers: Mallinckrodt (NYSE:MNK) +50%. InspireMD (NYSEMKT:NSPR) +26%. Endo International (NASDAQ:ENDP) +22%. Mesoblast MESO +16%. Adaptimmune Therapeutics (NASDAQ:ADAP) +16%.Losers: Emmaus Life Scienc

Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy

From Zacks Investment Research Sep 10, 2019

Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

F

Strong Sell

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!